• PRM267 - WHAT IS DRIVING NICE-DECISION MAKING ON SINGLE-ARM TRIALS?

    Oct 1, 2018, 00:00

  • PCV9 - VENOUS THROMBOEMBOLISM PROPHYLAXIS STRATEGIES FOR PEOPLE UNDERGOING ELECTIVE TOTAL KNEE REPLACEMENT- A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS TO INFORM NICE CLINICAL GUIDELINE RECOMMENDATION

    Oct 1, 2018, 00:00

  • PMD40 - THE BUDGET IMPACT AND COST-CONSEQUENCE OF TREATING LEG ULCERS WITH URGOSTART

    Oct 1, 2018, 00:00

  • PGI4 - REAL-WORLD TRENDS IN CLINICAL CHARACTERISTICS OF INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS INITIATING VEDOLIZUMAB OVER TIME IN ISRAEL

    Oct 1, 2018, 00:00

  • HT4 - PAN-EUROPEAN HTA – WHERE WE HAVE BEEN, WHERE WE ARE GOING?

    Oct 1, 2018, 00:00

  • PCN368 - CONCORDANCE BETWEEN PATIENTS AND CLINICIANS’ REPORTING OF SYMPTOMATIC ADVERSE EVENTS IN CANCER CLINICAL TRIALS- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMD113 - COST–UTILITY OF SURGICAL SUTURELESS BIOPROSTHESES VS. TAVI IN AORTIC VALVE REPLACEMENT FOR PATIENTS AT INTERMEDIATE AND HIGH SURGICAL RISK

    Oct 1, 2018, 00:00

  • PSY153 - UNDERSTANDING PATTERNS OF 30-DAY READMISSION IN PATIENTS WITH CARDIAC AMYLOIDOSIS

    Oct 1, 2018, 00:00

  • PND7 - AN EXPLORATORY ANALYSIS OF EFFICACY OF OCRELIZUMAB FOR MULTIPLE SCLEROSIS PATIENTS WITH INCREASED DISABILITY

    Oct 1, 2018, 00:00

  • PCV68 - POTENTIAL SAVINGS IN HIGHEST PRESCRIBING REGIONS FOR DIRECT-ACTING ORAL ANTICOAGULANTS IN ENGLAND

    Oct 1, 2018, 00:00

  • PCV54 - ESTIMATED ECONOMIC BURDEN OF ATRIAL FIBRILLATION IN GERMANY, ITALY, AND THE UK

    Oct 1, 2018, 00:00

  • PHP62 - HOME BREWED AUTOLOGOUS THERAPIES- CAN BIOPHARMA WIN THE WAR WITH DOMESTIC AUTOLOGOUS CELL GENE THERAPY MANUFACTURERS?

    Oct 1, 2018, 00:00

  • QL3 - EQ-5D-5L IS MORE RESPONSIVE THAN EQ-5D-3L TO TREATMENT BENEFIT OF CATARACT SURGERY

    Oct 1, 2018, 00:00

  • PHP81 - COMPARISON OF SELECTED DRUGS PRICES IN EU COUNTRIES

    Oct 1, 2018, 00:00

  • PCN3 - REAL WORLD EVIDENCE OF METASTATIC BREAST CANCER TREATMENT- A COMPARISON OF ADVERSE EFFECTS BETWEEN PALBOCICLIB TREATMENT AND ENDOCRINE THERAPY

    Oct 1, 2018, 00:00

  • PHP264 - QUALITATIVE ANALYSIS OF CLINICAL TRIALS RELATED TO DIABETES REGISTERED WITH CLINICAL TRIAL REGISTRY OF INDIA

    Oct 1, 2018, 00:00

  • PMD48 - COSTS IN THE DIAGNOSIS OF SPANISH PATIENTS WITH SUSPECTED RHEUMATOID ARTHRITIS DEPENDS ON THE CCP ASSAY USED – A COMPARISON OF AUTOMATED CCP 2 AND CCP 3 ASSAYS

    Oct 1, 2018, 00:00

  • PRS80 - HEALTH TECHNOLOGY ASSESSMENT DECISIONS FOR NOVEL ASTHMA THERAPIES- RESULTS, RATIONALE, AND TRENDS

    Oct 1, 2018, 00:00

  • PCV76 - COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN IN THE SECONDARY PREVENTION OF ACUTE CORONARY SYNDROMES IN GREECE

    Oct 1, 2018, 00:00

  • PCN67 - BUDGET IMPACT MODEL OF SUBCUTANEOUS RITUXIMAB COMPARED WITH INTRAVENOUS RITUXIMAB ON THE TREATMENT OF CD-20 POSITIVE NON-HODGKIN LYMPHOMA IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

    Oct 1, 2018, 00:00

  • PSY188 - USE OF MANAGED ENTRY AGREEMENTS IN INFLAMMATORY DISORDERS AMONG KEY HEALTH TECHNOLOGY ASSESSMENT AGENCIES

    Oct 1, 2018, 00:00

  • PMU61 - BEYOND THE COST-EFFECTIVENESS ACCEPTABILITY CURVE- THE APPROPRIATENESS OF RANK PROBABILITIES FOR PRESENTING THE RESULTS OF ECONOMIC EVALUATION IN MULTIPLE TECHNOLOGY APPRAISAL

    Oct 1, 2018, 00:00

  • PIN123 - USING EQ-5D TO MEASURE QUALITY OF LIFE IN PATIENTS WITH DIABETIC FOOT ULCERS AND VENOUS LEG ULCERS

    Oct 1, 2018, 00:00

  • PDB61 - COST-EFFECTIVENESS ANALYSIS OF HUMAN OR ANALOGUE BASAL INSULIN-SUPPORTED ORAL THERAPY IN TYPE 2 DIABETES IN HUNGARY

    Oct 1, 2018, 00:00

  • PMD24 - ASSOCIATION BETWEEN IOL DESIGN AND INCIDENCE OF PCO AND ND-YAG CAPSULOTOMY- A RETROSPECTIVE REAL WORLD EVIDENCE STUDY IN THE UK

    Oct 1, 2018, 00:00

  • PCN333 - REAL-WORLD TREATMENT PATTERNS OF PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER CLASSIFIED AS RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • PMD125 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN FRAGILITY FRACTURE SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP270 - POPULARITY OF NURSING PROFESSION AMONGST STUDENTS WHO ARE BEFORE THE CAREER CHOICE

    Oct 1, 2018, 00:00

  • PCP33 - COULD THE US ADMINISTRATION IMPOSE DRUG PRICE RAISES IN THE EUROPEAN UNION (EU)?

    Oct 1, 2018, 00:00

  • PIH11 - ANTIEMETIC USE IN PREGNANCY AND THE RISK OF MAJOR CONGENITAL MALFORMATIONS- A POPULATION-BASED COHORT STUDY

    Oct 1, 2018, 00:00

  • PCN4 - EFFECTIVENESS AND SAFETY OF PEMBROLIZUMAB IN ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PMS47 - COST-EFFECTIVENESS OF TOFACITINIB COMPARED WITH ADALIMUMAB IN THE TREATMENT OF MODERATE TO SEVERE RHEUMATOID ARTHRITIS IN IRAN

    Oct 1, 2018, 00:00

  • PDB128 - COMPARISON OF PATIENT ACTIVATION LEVELS ACROSS VARIOUS CONDITIONS IN THE US AND EU5

    Oct 1, 2018, 00:00

  • PND34 - PAYER AND SOCIETAL BENEFIT OF PEGINTERFERON BETA-1A VERSUS GLATIRAMER ACETATE IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN

    Oct 1, 2018, 00:00

  • PIN107 - BACTERIAL SKIN AND SOFT TISSUE INFECTIONS- GLOBAL MAPPING BY GEOGRAPHICAL DISTRIBUTION AND CLIMATE AREA

    Oct 1, 2018, 00:00

  • PRS54 - COST-EFFECTIVENESS ANALYSIS OF RESLIZUMAB FOR PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA INADEQUATELY CONTROLLED WITH HIGH-DOSE INHALED CORTICOSTEROIDS AND LONG-ACTING B2-AGONISTS IN SOUTH KOREA

    Oct 1, 2018, 00:00

  • PHP354 - THE IMPACT OF DATA PRIVACY REGULATIONS ON DRUG UTILIZATION DATA SHARING FOR INNOVATIVE PRICING ARRANGEMENTS

    Oct 1, 2018, 00:00

  • PSY56 - COST-UTILITY OF NEW FILM-COATED TABLET FORMULATION OF DEFERASIROX VERSUS DEFEROXAMINE AMONG MAJOR B-THALASSEMIA PATIENTS IN IRAN

    Oct 1, 2018, 00:00

  • PHP173 - PHARMACEUTICAL PROCUREMENT IN UKRAINE- AN ANALYSIS OF NEW TRENDS IN IMPROVING ACCESS TO MEDICINES

    Oct 1, 2018, 00:00

  • PHP19 - ANALYSIS OF ONE-DAY SURGERY INTERVENTIONS AMONG PATIENTS UNDER THE AGE OF 18 IN HUNGARY

    Oct 1, 2018, 00:00

  • PMD124 - CLINICAL, PATIENT-REPORTED OUTCOME MEASURES (PROMS) AND ECONOMIC OUTCOMES ASSOCIATED WITH ENHANCED RECOVERY PROGRAMS IN BARIATRIC SURGERY IN EUROPE, THE MIDDLE EAST AND AFRICA- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PRM214 - DO UTILITY VALUES USED IN HEALTH TECHNOLOGY ASSESSMENT MAINLY COME FROM WIDELY CITED REFERENCES?

    Oct 1, 2018, 00:00

  • PDB79 - COST-UTILITY ANALYSIS OF INSULIN GLARGINE 300 U/ML VERSUS INSULIN GLARGINE 100 U/ML AND INSULIN DEGLUDEC 100 U/ML IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN CROATIA

    Oct 1, 2018, 00:00

  • PHP307 - REIMBURSEMENT OF ADVANCED THERAPY MEDICINAL PRODUCTS IN EUROPE

    Oct 1, 2018, 00:00

  • PRM132 - MODELING MULTIPLE CARDIOVASCULAR EVENT HISTORY USING NESTED PARTITIONED SURVIVAL MODELS

    Oct 1, 2018, 00:00

  • PRM177 - CAN THE EQ-5D HELP UNDERSTAND HOW CHANGES IN CLINICAL OUTCOMES IMPACT ON DIFFERENT CONCEPTS OF HEALTH?

    Oct 1, 2018, 00:00

  • PMU78 - MEDICATION THERAPY MANAGEMENT WITH DIRECT PATIENT ENGAGEMENT TO ADDRESS NON-ADHERENCE TO SPECIALTY DRUGS

    Oct 1, 2018, 00:00

  • PND134 - THE EFFECT OF PHYSICAL ACTIVITY ON THE MOTOR ASPECTS OF DAILY LIVING OF PARKINSON’S DISEASE PATIENTS

    Oct 1, 2018, 00:00

  • PHP212 - A DECADE OF PUBLIC-PRIVATE PARTNERSHIPS (PDPS) IN BRAZIL- AN EXPLORATORY ANALYSIS OF PROGRESS AND CHALLENGES

    Oct 1, 2018, 00:00

  • PSY205 - BODY IMAGE IN SLE AND THE RELATIONSHIP BETWEEN DISEASE ACTIVITY AND PSYCHOSOCIAL CONCERNS

    Oct 1, 2018, 00:00

  • PMH19 - BUDGET IMPACT ANALYSIS OF INHALED LOXAPINE FOR THE MANAGEMENT OF PSYCHOMOTOR AGITATION IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER IN ITALY

    Oct 1, 2018, 00:00

  • PMS65 - MYOTONIC DISORDERS- ANALYSIS FROM THE FRENCH DRG-BASED INFORMATION SYSTEM (PMSI)

    Oct 1, 2018, 00:00

  • PMD46 - COST-COST MODEL FOR RULING OUT CORONARY ARTERY DISEASE IN SYMPTOMATIC PATIENTS WITH ULTRA-SENSITIVE PHONOCARDIOGRAPHY IN THE GERMAN AMBULATORY SECTOR

    Oct 1, 2018, 00:00

  • PCN77 - BUDGET IMPACT ANALYSIS OF BLINATUMOMAB FOR THE TREATMENT OF PEDIATRIC PATIENTS WITH PHILADELPHIA NEGATIVE RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN MEXICO

    Oct 1, 2018, 00:00

  • PCN182 - COST-EFFECTIVENESS RANDOMIZED STUDY OF LAPAROSCOPIC VERSUS OPEN BILATERAL INGUINAL HERNIA REPAIR

    Oct 1, 2018, 00:00

  • PCV96 - HEALTHCARE RESOURCE UTLISATION IN PATIENTS ON LIPID-LOWERING THERAPIES OUTSIDE OF WESTERN EUROPE- FINDINGS OF THE INTERNATIONAL CHOLESTEROL MANAGEMENT PRACTICE STUDY (ICLPS)

    Oct 1, 2018, 00:00

  • PCN240 - ALL-COMERS VS. BIOMARKER BASED PATIENT SELECTION FOR BIOTHERAPIES IN ONCOLOGY- IMPACT ON DRUG DEVELOPMENT AND MARKET ACCESS

    Oct 1, 2018, 00:00

  • PHP18 - COULD THE ONE-DAY SURGERY PLAY A SIGNIFICANT ROLE IN CATARACT WAITING LIST REDUCTION PROCESS IN HUNGARY?

    Oct 1, 2018, 00:00

  • PIN77 - DELAY BETWEEN HIV DIAGNOSIS AND TREATMENT INITIATION ACROSS THE EU5

    Oct 1, 2018, 00:00

  • PCN236 - IMPLICATIONS OF THE FAST EVOLVING THERAPEUTIC LANDSCAPE ON APPROPRIATE COMPARATORS IN ONCOLOGICAL AMNOG BENEFIT ASSESSMENTS

    Oct 1, 2018, 00:00

  • PMU34 - PRICE ANALYSIS OF VACCIENS MARKETED IN THE GULF COOPERATION COUNCIL COUNTRIES- A CROSS-SECTIONAL STUDY

    Oct 1, 2018, 00:00

  • PSY180 - UK HEALTH TECHNOLOGY ASSESSMENT OF ORPHAN DRUGS FOR RARE ONCOLOGY VERSUS RARE DISEASE- DOES ORPHAN DESIGNATION MAKE ANY DIFFERENCE IN HTA PROCESS?

    Oct 1, 2018, 00:00

  • PGI6 - 30-DAY MORTALITY RATES FOLLOWING HOSPITAL ADMISSION FOR ULCERATIVE COLITIS AND CLOSTRIDIUM DIFFICILE INFECTION

    Oct 1, 2018, 00:00

  • PIN71 - ADENOVIRUS VIREMIA IS AN INDEPENDENT PREDICTOR OF PROLONGED TRANSPLANTATION HOSPITALIZATION IN PEDIATRIC ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS- FINDINGS FROM ADVANCE

    Oct 1, 2018, 00:00

  • PCV69 - COST-EFFECTIVENESS OF IVABRADINE AS A PHARMACOTHERAPY OPTION FOR PATIENTS WITH CONGESTIVE HEART FAILURE- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PRM145 - A NEW GRAPHICAL REPRESENTATION OF PROBABILITY SENSITIVITY ANALYSIS RESULTS AS AN ALTERNATIVE FOR THE SCATTER-PLOT

    Oct 1, 2018, 00:00

  • PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK

    Oct 1, 2018, 00:00

  • PIH54 - A GLOBAL REVIEW OF QUALITY OF LIFE IMPACT OF ATOPIC DERMATITIS IN CHILDREN

    Oct 1, 2018, 00:00

  • PMS87 - IMPACT OF SERIOUS ILLNESS MEDICAL ASSISTANCE POLICY ON PERSISTENCE WITH TERIPARATIDE IN OSTEOPOROSIS PATIENTS IN QINGDAO, CHINA

    Oct 1, 2018, 00:00

  • PDB32 - SEX- AND SITE-SPECIFIC DIFFERENCES IN COLORECTAL CANCER RISK AMONG PEOPLE WITH TYPE 2 DIABETES

    Oct 1, 2018, 00:00

  • PSY122 - MANAGEMENT OF POOR PROGNOSIS MULTIPLE MYELOMA PATIENTS UNDER REGULAR CLINICAL CONDITIONS IN SPAIN

    Oct 1, 2018, 00:00

  • PCN73 - BUDGET IMPACT OF IXAZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA IN RUSSIA

    Oct 1, 2018, 00:00

  • PIH53 - COMPARISON OF THE EQ-5D-5L AND THE EQ-5D-3L USING INDIVIDUAL PATIENT DATA FROM REFORM TRIAL

    Oct 1, 2018, 00:00

  • PCN259 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH MELANOMA CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PDB10 - MACROVASCULAR AND MICROVASCULAR COMPLICATIONS OF TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATED FREQUENCY OF HOSPITAL ADMISSION

    Oct 1, 2018, 00:00

  • PMD16 - HEALTH ECONOMIC EVALUATION OF AN ULTRATHIN, BIORESORBABLE POLYMER SIROLIMUS-ELUTING CORONARY STENT COMPARED TO A THIN, DURABLE POLYMER EVEROLIMUS-ELUTING STENT

    Oct 1, 2018, 00:00

  • PHP225 - ASSESSMENT OF THE UNIT COSTS IN IMAGING ACTS- THE EXAMPLE OF MRI AND CT-SCAN ACTS IN FRANCE

    Oct 1, 2018, 00:00

  • PHP124 - INTRANSPARENT EXCEPTIONAL FUNDING IN FRANCE ENSURING CONTINUITY OF PATIENT ACCESS TO INNOVATIVE TREATMENT

    Oct 1, 2018, 00:00

  • PMD133 - SUCCESS FACTORS FOR §137H SGB V ASSESSMENT OF MEDICAL DEVICES IN GERMANY

    Oct 1, 2018, 00:00

  • PCV58 - HEALTH INSURANCE TREATMENT COST OF SECONDARY HYPERTENSION IN HUNGARY- A NATIONWIDE COST OF ILLNESS STUDY

    Oct 1, 2018, 00:00

  • PDB3 - THE IMPACT OF GLYCATED HEMOGLOBIN CONTROL ON MORBIDITY AND SURVIVAL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN155 - COST-EFFECTIVENESS OF CPX-351 VERSUS 3+7 AMONG PATIENTS 60 YEARS OF AGE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PCN355 - UTILITY IN FRENCH HEALTH-ECONOMIC OPINIONS- KEY LEARNINGS OF A RETROSPECTIVE ANALYSIS IN ONCOLOGY DRUGS

    Oct 1, 2018, 00:00

  • PMS8 - REAL-WORLD USE OF PROPHYLACTIC ANTIBIOTICS IN TOTAL KNEE ARTHROPLASTY

    Oct 1, 2018, 00:00

  • PCN384 - HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ADVANCED (STAGE II-IV) OVARIAN CANCER RESISTANT OR REFRACTORY TO FRONTLINE PLATINUM-BASED THERAPY

    Oct 1, 2018, 00:00

  • PRM115 - MODELING DECLINE IN COGNITION TO DECLINE IN FUNCTION IN ALZHEIMER’S DISEASE (AD)

    Oct 1, 2018, 00:00

  • PMD80 - IS SCREENING FOR OVARIAN CANCER EFFECTIVE AND COST EFFECTIVE IN AUSTRIA? A MODEL-BASED ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PCV115 - QUALITY OF INR CONTROL AND SWITCHING TO DOAC BETWEEN WOMEN AND MEN WITH ATRIAL FIBRILLATION TREATED WITH VITAMIN K ANTAGONISTS IN SPAIN. A POPULATION-BASED, REAL-WORLD STUDY.

    Oct 1, 2018, 00:00

  • PND99 - CYSTIC FIBROSIS THERAPIES - KEY DRIVERS BEHIND DIFFERING HTA DECISIONS

    Oct 1, 2018, 00:00

  • MD1 - EVIDENCE DEVELOPMENT TIMELINE OF MEDICAL DEVICES IN THE UK- WHERE DO MEDICAL INNOVATION BRIEFINGS FIT?

    Oct 1, 2018, 00:00

  • PMH8 - DEPRESSION IS ASSOCIATED WITH CHRONIC DISORDERS IN CHILDREN AND ADOLESCENTS

    Oct 1, 2018, 00:00

  • QL4 - ASSESSMENT OF QUALITY OF LIFE IN PATIENTS WITH METASTATIC MELANOMA IN REAL CLINICAL PRACTICE IN FRANCE

    Oct 1, 2018, 00:00

  • PMD31 - THE CONCORDANCE AND BUDGET IMPACT OF MULTIPLE ER, PR AND HER2 DETERMINATIONS IN DUTCH BREAST CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PUK15 - PHARMACOECONOMICS MODES OF ANTIBIOTIC THERAPYOF UNCOMPLICATED COMMUNITY-ACQUIRED ACUTE PYELONEPHRITIS IN A MULTIDISCIPLINARY HOSPITALS

    Oct 1, 2018, 00:00

  • PCN222 - TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILISATION (HCRU) IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC) IN CANADA AND EUROPE

    Oct 1, 2018, 00:00

  • PRM184 - ANALYSIS OF UTILITY VALUES USED IN NICE APPRAISALS OF HIGHLY SPECIALISED TECHNOLOGIES

    Oct 1, 2018, 00:00

  • PRM232 - LONGITUDINAL MATCHING- A METHOD FOR GENERATING COMPARABLE SAMPLES OF TREATED AND TREATMENT-NAÏVE PATIENTS WITH PROGRESSIVE CONDITIONS

    Oct 1, 2018, 00:00

  • PCN320 - RECOMMENDATIONS OF SPANISH THERAPEUTIC POSITIONING REPORTS FOR NEW ONCOLOGY DRUGS SINCE YEAR 2013

    Oct 1, 2018, 00:00

  • PMU32 - ORPHAN DRUG PRICES IN EUROPE- IMPACT OF EXTERNAL REFERENCE PRICING

    Oct 1, 2018, 00:00

  • PSY157 - EMERGING RHEUMATOID ARTHRITIS AND PSORIASIS BIOLOGICS- HOW TO THRIVE IN THE FACE OF BIOSIMILAR COMPETITION?

    Oct 1, 2018, 00:00

  • PDB94 - INITIAL ANTIDIABETIC PHARMACOTHERAPY PRESCRIBED TO PATIENTS WITH NEWLY DIAGNOSED TYPE-2 DIABETES IN A COMMERCIAL HEALTH PLAN IN THE UNITED STATED

    Oct 1, 2018, 00:00

  • PHP321 - THE HTA APPROACH OF NOVEL TREATMENTS IN THE CENTRAL EASTERN EUROPEAN COUNTRY FOR FIVE YEARS PERIOD (2013-2017)- THE CASE OF BULGARIA

    Oct 1, 2018, 00:00

  • PHP233 - DIVERGENCE IN UK HTA RECOMMENDATIONS- NOT ALWAYS A NICE OUTCOME

    Oct 1, 2018, 00:00

  • PMD11 - STAGING INVESTIGATION STRATEGIES FOR DISTANT METASTASES DETECTION IN WOMEN WITH BREAST CANCER- A SYSTEMATIC REVIEW AND META-ANALYSIS

    Oct 1, 2018, 00:00

  • PCN377 - RESPONSE SHIFT EFFECT ON QUALITY OF LIFE IN RANDOMIZED CONTROL TRIAL OF TAXANE VERSUS S-1 FOR METASTATIC BREAST CANCER PATIENTS (SELECT-BC)- STRUCTURAL EQUATION MODELING

    Oct 1, 2018, 00:00

  • PHP341 - ARE THERE ENOUGH REGULATIONS TO COMBAT THE POOR QUALITY POVIDONE-IODINE IN EGYPT

    Oct 1, 2018, 00:00

  • PHP302 - HOW AFFORDABILITY IS CONSIDERED FOR PRICING POLICIES?

    Oct 1, 2018, 00:00

  • PMD130 - HEALTH TECHNOLOGY ASSESSMENT (HTA) OF MEDICAL DEVICES IN EUROPE- THE CALM BEFORE THE STORM OR ALREADY WIND FORCE 8?

    Oct 1, 2018, 00:00

  • PRS97 - PATIENT REPORTED OUTCOMES IN COPD CLINICAL TRIALS- TRENDS AND GAPS

    Oct 1, 2018, 00:00

  • PCN309 - DIVERSITY IN SAFETY DATA ANALYSES IN GERMAN AMNOG BENEFIT ASSESSMENTS FOR MULTIPLE MYELOMA

    Oct 1, 2018, 00:00

  • PND39 - MULTIPLE SCLEROSIS BURDEN OF ILLNESS STUDY FOR TURKEY

    Oct 1, 2018, 00:00

  • PSY185 - ALTERNATIVE METHODOLOGIES IMPLEMENTED BY HTA AGENCIES FOR ORPHAN DRUGS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PDB58 - REIMBURSEMENT FOR TYPE 2 DIABETES MELLITUS PATIENTS HOSPITALIZED IN A MUNICIPAL HOSPITAL IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PMS101 - EVAULATION OF OUTCOMES AND PHYSIOTERAPY REHABILITATION AFTER DIRECT ANTERIOR APPROACH OF TOTAL HIP ARTHROPLASTY COMPARED TO CONVENTIONAL ANTEROLATERAL APPROACH

    Oct 1, 2018, 00:00

  • CN5 - COST-EFFECTIVENESS OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE CHEMOTHERAPIES FOR FIRST-LINE TREATMENT OF PD-L1 POSITIVE (≥50%) METASTATIC NON-SMALL CELL LUNG CANCER IN FRANCE

    Oct 1, 2018, 00:00

  • PIH24 - MODELLED EFFECTS OF A PEDIATRIC TRIPLE-CHAMBER-BAG (3CB) SYSTEM ON PAYER COSTS AND CLINICAL OUTCOMES IN PRE-TERM NEONATES ACROSS FRANCE, GERMANY AND ITALY

    Oct 1, 2018, 00:00

  • PCN120 - EPIDEMIOLOGY AND COSTS OF NON-SMALL CELL LUNG CANCER (NSCLC) IN AUSTRIA

    Oct 1, 2018, 00:00

  • PDB110 - TREATMENT PERSISTENCE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH GLP-1 RECEPTOR AGONISTS IN CLINICAL PRACTICE IN SWEDEN- NATIONWIDE RETROSPECTIVE COHORT STUDY

    Oct 1, 2018, 00:00

  • PND3 - SYSTEMATIC LITERATURE REVIEW ON THE EFFICACY AND SAFETY OF ANTIEPILEPTIC DRUGS IN PAEDIATRIC PATIENTS WITH FOCAL SEIZURES – ARE CURRENTLY APPROVED THERAPIES SUFFICIENT FOR THE MANAGEMENT OF PAEDIATRIC PATIENTS?

    Oct 1, 2018, 00:00

  • PRM219 - A NOVEL MEASURE OF DRUG BENEFIT-RISK ASSESSMENT BASED ON SCALE LOSS SCORE (SLOS)

    Oct 1, 2018, 00:00

  • PMH49 - LAUNCHING LONG ACTING PRODUCTS TO TREAT OPIOID USE DISORDER- ARE PAYERS WILLING TO PAY PREMIUM PRICE?

    Oct 1, 2018, 00:00

  • PCN83 - THE USE OF OBINUTUZUMAB IN TREATMENT OF REFRACTORY AND RELAPSING FOLLICULAR LYMPHOMA

    Oct 1, 2018, 00:00

  • PCN221 - STAGE III UNRESECTABLE NON-SMALL CELL LUNG CANCER TREATMENT PATTERNS AND COSTS- AN ONTARIO, CANADA ANALYSIS

    Oct 1, 2018, 00:00

  • PSY142 - THE ACCESS (TIMING AND AVAILABILITY) OF ORPHAN MEDICINE USE AND ITS DETERMINANTS AMONG OECD COUNTRIES FROM 2006 THROUGH 2016

    Oct 1, 2018, 00:00

  • PDB74 - IDEGLIRA VERSUS IGLARLIXI FOR PATIENTS WITH INADEQUATELY CONTROLLED TYPE 2 DIABETES ON BASAL INSULIN- A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PIN115 - BARRIERS TO ACCESS AND IMPLEMENTATION OF ROTAVIRUS VACCINATION IN EUROPE

    Oct 1, 2018, 00:00

  • PND59 - COST EFFECTIVENESS ANALYSIS OF ALEMTUZUMAB AS A TREATMENT OPTION FOR PATIENTS WITH MULTIPLE SCLEROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PMU53 - HOSPITAL COSTS OF SPINAL LUMBAR FUSION SURGERIES WITH NEUROMONITORING

    Oct 1, 2018, 00:00

  • PCN64 - REVIEW OF NICE HTA SUBMISSIONS INCLUDING METHODOLOGIES ADJUSTING FOR OVERALL SURVIVAL IN THE PRESENCE OF TREATMENT SWITCHING

    Oct 1, 2018, 00:00

  • PGI47 - OPIOID USAGE AND PATIENT-REPORTED PAIN SCORES IN IRRITABLE BOWEL SYNDROME PATIENTS- A RETROSPECTIVE ANALYSIS OF A LARGE U.S. ELECTRONIC HEALTH RECORD DATABASE

    Oct 1, 2018, 00:00

  • PMD64 - THE ROLE OF INFORMATION PROVISION IN ECONOMIC EVALUATIONS OF NON-INVASIVE PRENATAL TESTING- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP323 - ESTABLISHING AN ALIGNED VIEW OF MODERN, FORWARD-LOOKING HTA PROCESS

    Oct 1, 2018, 00:00

  • PSY49 - BUDGETARY IMPACT OF ORPHAN DRUGS IN THE CATALAN HEALTHCARE SERVICE

    Oct 1, 2018, 00:00

  • PSY64 - BLEEDING EPISODES, THE MOST IMPACTFUL VARIABLE IN THE TREATMENT COST OF THE HEMOPHILIA A IN COLOMBIA. DATA FROM THE LITERATURE AND THE REAL LIFE

    Oct 1, 2018, 00:00

  • PND113 - HEALTH TECHNOLOGY ASSESSMENT OF MRGFUS FOR THE TREATMENT OF ESSENTIAL TREMOR IN THE ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PHP77 - EFFECT OF NEW INDICATIONS ON THE PRICE DEVELOPMENT OF NEW MEDICINAL PRODUCTS IN GERMANY

    Oct 1, 2018, 00:00

  • PSY80 - THE COST OF HEALTHCARE FOR CHILDREN WITH SICKLE CELL DISEASE- AN ANALYSIS OF HEALTHCARE UTILIZATION AND EXPENDITURES IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PSY46 - A DYNAMIC APPROACH FOR BUDGET IMPACT ANALYSIS (BIA) IN ONCOLOGY – THE CASE OF NOVEL TREATMENT COMBINATIONS FOR FRONTLINE TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TIE NDMM)

    Oct 1, 2018, 00:00

  • PCP55 - REVIEW AND RECOMMENDATIONS OF ENDPOINTS FOR REAL-WORLD STUDIES IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PMU56 - ECONOMIC EVALUATION OF POSACONAZOLE IN COMPARISON WITH LIPOSOMAL AMPHOTERICIN B IN THE TREATMENT OF MUCORMYCOSIS IN IRAN

    Oct 1, 2018, 00:00

  • PRM6 - INCREASED RISK OF CUTANEOUS ADVERSE DRUG REACTION AMONG OLDER ADULTS EXPOSED TO POLYPHARMACY

    Oct 1, 2018, 00:00

  • PRM4 - A CASE STUDY IN CHOOSING WISELY RECOMMENDATION ADOPTION- SINGLE FRACTION RADIATION TREATMENT OF BONE METASTASES

    Oct 1, 2018, 00:00

  • PRM79 - WEBER EFFECT- AN EXTENDED ANALYSIS FOR TEN YEARS OF REPORTING TRENDS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS)

    Oct 1, 2018, 00:00

  • PND111 - ELICITING PREFERENCES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS – A BRAZILIAN STUDY USING A MULTICRITERIA DECISION ANALYSIS (MCDA) APPROACH

    Oct 1, 2018, 00:00

  • PSY148 - PRIMARY NON-ADHERENCE AMONG NEWLY DIAGNOSED RHEUMATOID ARTHRITIS PATIENTS

    Oct 1, 2018, 00:00

  • PMH39 - HEALTH-ECONOMIC EVALUATION OF PHARMACOGENETIC TESTS IN PSYCHIATRIC IN-PATIENT CARE

    Oct 1, 2018, 00:00

  • PHP13 - USAGE OF DIETARY SUPPLEMENTS BY GYM VISITING ATHLETES – EFFECTS, AWARENESS AND CONSCIOUSNESS

    Oct 1, 2018, 00:00

  • PSS59 - CLINICAL CHARACTERISTICS OF BIOLOGIC ELIGIBLE HIDRADENITIS SUPPURATIVA PATIENTS IN EU5

    Oct 1, 2018, 00:00

  • PCV75 - AN UPDATED COST-EFFECTIVENESS PAIRWISE ANALYSIS OF APIXABAN AND WARFARIN FOR STROKE PREVENTION IN PATIENTS WITH NON- VALVULAR ATRIAL FIBRILLATION IN FRANCE

    Oct 1, 2018, 00:00

  • PSY70 - MANAGEMENT COSTS OF CHEMOTHERAPY AND ALLOGENEIC STEM-CELL TRANSPLANT OF CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA IN FRANCE

    Oct 1, 2018, 00:00

  • PIH30 - ASSESSMENT OF TREATMENT PATTERN IN PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME (PCOS) IN A TERTIARY CARE HOSPITAL IN URBAN SETTING

    Oct 1, 2018, 00:00

  • PMS97 - THE EFFECT OF NEUROMUSCULAR AND NEUROMUSCULAR-CORE TRAINING ON INJURY PREVENTION

    Oct 1, 2018, 00:00

  • PCN153 - COST-EFFECTIVENESS ANALYSIS OF APALUTAMIDE FOR TREATMENT IN NON- METASTASIS CASTRATION-RESISTANT PROSTATE CANCER

    Oct 1, 2018, 00:00

  • PHP261 - IMPACT OF DYNAMIC CHANGES OF THE DEFINITION OF THE APPROPRIATE COMPARATIVE THERAPY (ACT) ON MARKET ACCESS PERFORMANCE OF NEW ACTIVE SUBSTANCES IN GERMANY

    Oct 1, 2018, 00:00

  • PCP54 - OVERVIEW OF METHODS FOR ASSESSING COMPARATIVE EVIDENCE FOR TREATMENTS EVALUATED IN EARLY PHASE TRIALS IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PRM241 - AN OUT-OF-SAMPLE METHOD TO QUANTIFY SYSTEMATIC ERROR IN UNANCHORED INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PDB78 - ECONOMIC EVALUATION OF DAPAGLIFLOZIN AS ADD-ON TO METFORMIN FOR T2DM TREATMENT IN THE ISRAELI HEALTHCARE SETTING

    Oct 1, 2018, 00:00

  • PCN287 - ANALYSIS OF IMPACTS OF THE SUPPLEMENTARY SCHEMES ON THE DRUG REIMBURSEMENT DECESION-MAKING UNDER THE POSITIVE LIST SYSTEM IN KOREA

    Oct 1, 2018, 00:00

  • PHP205 - BARRIERS TO AND FACILITATORS OF THE APPLICATION OF HEALTH TECHNOLOGY ASSESSMENT IN MEDICINE PRICING AND REIMBURSEMENT POLICIES IN INDONESIA

    Oct 1, 2018, 00:00

  • PND142 - FRENCH DATA FROM A WORLDWIDE PATIENT SURVEY ON ECONOMIC IMPACT OF MIGRAINE

    Oct 1, 2018, 00:00

  • PCV31 - ANTICOAGULANTS IN OLDER PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION AFTER INTRACRANIAL HEMORRHAGE

    Oct 1, 2018, 00:00

  • PDB135 - THE BURDEN OF DIABETES MELLITUS IN TAIWAN BASED ON PATIENT-REPORTED OUTCOMES

    Oct 1, 2018, 00:00

  • PSY11 - REAL-WORLD EXPERIENCE OF GENERALIZED LIPODYSTROPHY PATIENTS ENROLLED IN THE METRELEPTIN EARLY ACCESS PROGRAM- INITIAL RESULTS

    Oct 1, 2018, 00:00

  • PSY105 - COST-UTILITY OF NINTEDANIB VERSUS PIRFENIDONE FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS- A BELGIAN PERSPECTIVE

    Oct 1, 2018, 00:00

  • CN2 - PREDICTING UTILITY SCORES IN LOCALIZED PROSTATE CANCER- MAPPING FROM EPIC TO PORPUS

    Oct 1, 2018, 00:00

  • PHP322 - REAL-WORLD DATA - WHAT ARE THE USE AND REQUIREMENTS IN HEALTH-ECONOMIC APPRAISALS IN REINSCRIPTION BY THE FRENCH HAUTE AUTORITE DE SANTE (HAS)?

    Oct 1, 2018, 00:00

  • PHP328 - REAL-WORLD-DATA AND REAL-WORLD-EVIDENCE STATE OF ART FROM A LITERATURE REVIEW PERSPECTIVE

    Oct 1, 2018, 00:00

  • PRM39 - IS THE CHOICE OF WILLINGNESS-TO-PAY THRESHOLD IN COST-UTILITY ANALYSIS ENDOGENOUS TO THE RESULTING VALUE OF THE TECHNOLOGY?

    Oct 1, 2018, 00:00

  • PCN388 - PATIENT REPORTED OUTCOMES IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (PRO-CAPRI) IN THE NETHERLANDS

    Oct 1, 2018, 00:00

  • PRM80 - THE USE OF EXTERNAL DATA TO BETTER INFORM SURVIVAL EXTRAPOLATIONS IN SUBMISSIONS TO THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PCN206 - ANAPLASTIC LYMPHOMA KINASE (ALK) TESTING IN NON-SMALL CELL LUNG CARCINOMA (NSCLC)- RECOMMENDED TESTS AND COVERAGE POLICIES ACROSS ORGANISATION FOR ECONOMIC CO-OPERATION AND DEVELOPMENT (OECD) COUNTRIES

    Oct 1, 2018, 00:00

  • PMD29 - BUDGET IMPACT ANALYIS OF MECHANICHAL THROMBECTOMY IN THE TREATMENT OF ACUTE ISCHEMUC STROKE

    Oct 1, 2018, 00:00

  • PSY66 - AN EFFICIENT AMBULATORY SERVICE MODEL FOR HEMOPHILIC PATIENTS, A COST-BENEFIT APPROACH

    Oct 1, 2018, 00:00

  • PSY29 - REAL-WORLD DISCONTINUATION OF BIOLOGICAL TREATMENTS IN MODERATE-TO-SEVERE PLAQUE PSORIASIS OVER THE FIRST 5 YEARS OF TREATMENT – A LITERATURE REVIEW OF DRUG SURVIVAL

    Oct 1, 2018, 00:00

  • PIN12 - HOSPITALIZATIONS RELATED TO RESPIRATORY VIRAL INFECTIONS DURING THE 2017/18 SEASON IN THE VALENCIA REGION OF SPAIN

    Oct 1, 2018, 00:00

  • PCP44 - IMPLICATIONS OF GENOME-DRIVEN ONCOLOGY ON EVIDENCE REQUIREMENTS FOR HEALTH TECHNOLOGY ASSESSMENT

    Oct 1, 2018, 00:00

  • PMH7 - DURATION OF INABILITY TO WORK IN DEPRESSION PATIENTS TREATED IN GENERAL OR PSYCHIATRIC PRACTICES IN GERMANY

    Oct 1, 2018, 00:00

  • PCN74 - A BUDGET-IMPACT ANALYSIS OF ADJUVANT PERTUZUMAB AND TRASTUZUMAB IN EARLY HER2-POSITIVE BREAST CANCER

    Oct 1, 2018, 00:00

  • PCP17 - IMPACT OF THE ICER VALUE ASSESSMENT FRAMEWORK ON DRUG PRICING IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN107 - BURDEN AND COSTS OF ACUTE MYELOID LEUKAEMIA IN PORTUGAL

    Oct 1, 2018, 00:00

  • PHP70 - COUNTRY-SPECIFIC DRIVERS AND BARRIERS FOR MARKET ACCESS OF E-HEALTH SOLUTIONS

    Oct 1, 2018, 00:00

  • PCN261 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH COLORECTAL CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PRS26 - THE ECONOMIC BURDEN OF ASTHMA IN ADULTS IN GREECE

    Oct 1, 2018, 00:00

  • MO2 - MODELLING OVERALL SURVIVAL IN IMMUNOTHERAPY USING PARAMETRIC TECHNIQUES- AVELUMAB IN PREVIOUSLY TREATED METASTATIC MERKEL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PCV123 - ECONOMIC EVALUATION FOR ROSUVASTATIN VS. ATORVASTATIN IN EGYPTIAN PATIENTS WITH HYPERLIPIDEMIA EGYPT CASE

    Oct 1, 2018, 00:00

  • PMH2 - EXAMINING PARKINSON’S DISEASE PSYCHOSIS TREATMENT OUTCOMES IN THE REAL WORLD- THE INSYTE OBSERVATIONAL STUDY – INITIAL YEAR 1 INTERIM FINDINGS

    Oct 1, 2018, 00:00

  • PCN23 - EFFICIENCY OF NIVOLUMAB TREATMENT AFTER PLATINUM CHEMOTHERAPY IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN) IN SPAIN

    Oct 1, 2018, 00:00

  • PIN110 - COMPARISON OF DRUG ASSESSMENT REPORTS PUBLISHED BY FRENCH (HAS-CEESP) AND UK (NICE) HTAS- FOCUS ON HEPATITIS C

    Oct 1, 2018, 00:00

  • PMD4 - SYSTEMATIC REVIEW AND META-ANALYSIS OF DIAGNOSTIC TEST ACCURACY STUDIES- FLUORESCENCE ENZYME IMMUNOASSAY VERSUS INDIRECT IMMUNOFLUORESCENT ASSAYS FOR INITIAL SCREENING FOR CONNECTIVE TISSUE DISEASES

    Oct 1, 2018, 00:00

  • CP1 - MULTI-INDICATION THERAPIES- DEVELOPING A VALUE-BASED FRAMEWORK TO INCORPORATE OPPORTUNITY COST

    Oct 1, 2018, 00:00

  • PCN323 - PERJETA TREATMENT DURATION IN THE ITALIAN CLINICAL PRACTICE- A FIRST ANALYSIS OF THE AIFA PRESCRIPTION REGISTRY

    Oct 1, 2018, 00:00

  • PND25 - ECONOMIC ANALYSIS OF COMPREHENSIVE REHABILITATION EFFICIENCY WITH AND WITHOUT BOTULINUM NEUROTOXIN A INJECTIONS IN CHILDREN WITH SPASTIC CEREBRAL PALSY

    Oct 1, 2018, 00:00

  • PND4 - CLOBAZAM AS INTERMITENT PROPHYLAXIS IN TYPICAL FEBRILE SEIZURES AND THEIR ANEMIC STATUS

    Oct 1, 2018, 00:00

  • PMD110 - COST-EFFECTIVENESS OF IMMUNOADSORPTION FOR INCOMPATIBLE KIDNEY TRANSPLANTATION IN GERMANY

    Oct 1, 2018, 00:00

  • PMU37 - INTRODUCTION RATE OF NEW HEMATO-ONCOLOGY DRUGS IN CATALONIA

    Oct 1, 2018, 00:00

  • PRM212 - PATIENT EXPERIENCE WITH PLATINUM-RESISTANT OR PLATINUM-REFRACTORY OVARIAN CANCER

    Oct 1, 2018, 00:00

  • PCN201 - IMPACT OF COMORBID DEPRESSION ON RATES, COSTS, AND HEALTH CARE RESOURCE USE IN LUNG CANCER PATIENTS

    Oct 1, 2018, 00:00

  • PDB15 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS DIPEPTIDYL PEPTIDASE 4 (DPP-4) INHIBITORS- SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PRS51 - COMPARISON OF THE TREATMENT OPTIONS FOR COW'S MILK PROTEIN ALLERGY- A COST MINIMIZATION ANALYSIS BASED ON REAL WORLD CONDITIONS OF TURKEY

    Oct 1, 2018, 00:00

  • PCN316 - RELATIONSHIP BETWEEN TWO CANCER CLINICAL BENEFIT FRAMEWORKS AND HEALTH TECHNOLOGY DECISIONS IN THREE EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PMU110 - EXPLORING U.S. CONSUMERS’ KNOWLEDGE, ATTITUDES AND PRACTICES TOWARDS OVER-THE-COUNTER MEDICATIONS

    Oct 1, 2018, 00:00

  • PCP46 - A SIMPLE DECISION TREE TO IDENTIFY POTENTIAL APPLICATIONS OF MACHINE LEARNING AS AN ADDITION TO TRADITIONAL STATISTICAL ANALYSIS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH

    Oct 1, 2018, 00:00

  • PND104 - RECOMMENDATIONS FOR A NATIONAL MULTIPLE SCLEROSIS (MS) STRATEGY

    Oct 1, 2018, 00:00

  • PCN56 - TREATMENT EFFECT MODIFICATION (EM) OF ANTICANCER THERAPIES IN FIRST-LINE ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC)- A SYSTEMATIC ASSESSMENT OF TRIAL DATA

    Oct 1, 2018, 00:00

  • PDB114 - DRUG UTILIZATION STUDY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN AN ITALIAN REAL-WORLD SETTING- A RETROSPECTIVE STUDY

    Oct 1, 2018, 00:00

  • PMS18 - BUDGET IMPACT ANALYSIS OF KNEE OSTEOARTHRITIS VISCOSUPPLEMENTATION TREATMENT IN BRAZIL

    Oct 1, 2018, 00:00

  • PRS56 - COST-EFFECTIVENESS OF AMBULATORY OXYGEN IN IMPROVING QUALITY OF LIFE IN FIBROTIC LUNG DISEASE- A TALE OF TWO OUTCOMES

    Oct 1, 2018, 00:00

  • PRM70 - NON-SMALL CELL LUNG CANCER MARKET ANALYSIS FOR TARGETED THERAPIES IN TURKEY

    Oct 1, 2018, 00:00

  • PHP26 - EVOLUTION OF SICK PAY BENEFITS IN HUNGARY BETWEEN 2005 AND 2016

    Oct 1, 2018, 00:00

  • PMS119 - ACCEPTABILITY OF HEALTH PROBLEMS IN CHRONIC MUSCULOSKELETAL DISEASES

    Oct 1, 2018, 00:00

  • PRM29 - COMPARING OPTHALMOLOGY TREATMENTS VIA THE INTEGRATION OF IPD AND AGGREGATE-LEVEL DATA- WHICH MATCHING ADJUSTED INDIRECT COMPARISON (MAIC) APPROACH IS BEST?

    Oct 1, 2018, 00:00

  • PCV152 - TREATMENT BURDEN ASSOCIATED WITH DIFFERENT ANTICOAGULATION STRATEGIES OF ATRIAL FIBRILLATION PATIENTS- AN OBSERVATIONAL STUDY IN GERMANY, SWEDEN AND SWITZERLAND BASED ON THE ANTI-CLOT TREATMENT SCALE

    Oct 1, 2018, 00:00

  • PRS44 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS UMEC/VI IN PATIENTS WITH COPD- COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

    Oct 1, 2018, 00:00

  • PRM165 - INFLUENCE OF THE TIME HORIZON LENGTH ON THE RESULTS OF PHARMACOECONOMIC RESEARCH

    Oct 1, 2018, 00:00

  • PHP324 - NICE- A MULTIPROGRAM HTA ORGANIZATION TO SUIT ALL?

    Oct 1, 2018, 00:00

  • PCN89 - COST –EFFECTIVENESS ANALYSIS OF PERTUZUMAB AS FIRST LINE NEOADJUVANT TREATMENT OPTION FOR PATIENTS HER2 + BREAST CANCER IN REPUBLIC OF MACEDONIA

    Oct 1, 2018, 00:00

  • PRM97 - PATIENT VERSUS TREATMENT LINE LEVEL MATCHING- IMPACT ON COVARIATES BALANCE AND COST EFFECTIVENESS RESULTS, A CASE STUDY IN ONCOLOGY

    Oct 1, 2018, 00:00

  • PRS41 - COST-EFFECTIVENESS OF PIRFENIDONE FOR THE TREATMENT OF PATIENTS WITH MILD TO MODERATE IDIOPATHIC PULMONARY FIBROSIS IN GREECE

    Oct 1, 2018, 00:00

  • PCN147 - COST-EFFECTIVENESS SIMULATION AND ANALYSIS OF COLORECTAL CANCER SCREENING IN SHANGHAI POPULATION, CHINA- COMPARISON BETWEEN URBAN AND RURAL RESIDENTS

    Oct 1, 2018, 00:00

  • PRM33 - HUMAN CAPITAL VS. FRICTION COST APPROACH – DIFFERENCES IN THE PRESENCE OF DEATH AND LONG-TERM CONSEQUENCES

    Oct 1, 2018, 00:00

  • PMS13 - REAL-WORLD TREATMENT OF PATIENTS WITH OSTEOPOROSIS IN GERMANY- PREVALENCE AND INCIDENCE OF PATIENTS WITH OSTEOPOROSIS AT INCREASED FRACTURE RISK

    Oct 1, 2018, 00:00

  • PMS50 - COST-EFFECTIVENESS ANALYSIS OF APREMILAST IN THE TREATMENT OF PSORIATIC ARTHRITIS (PSA) IN THE SLOVAK REPUBLIC AND SLOVENIA

    Oct 1, 2018, 00:00

  • PDB96 - APPLYING MCDA FRAMEWORK IN PHARMACEUTICAL POLICY DECISION MAKING- A PILOT STUDY IN DIABETES MELLITUS TYPE 2

    Oct 1, 2018, 00:00

  • PHP74 - A REVIEW OF THE INFLUENCE OF INTERNATIONAL REFERENCE PRICING (IRP) ON LAUNCH SEQUENCING IN EUROPE

    Oct 1, 2018, 00:00

  • PMD182 - DISCRETE CHOICE EXPERIMENTS TO MEASURE PATIENTS' PREFERENCES FOR CORONARY REVASCULARIZATION.

    Oct 1, 2018, 00:00

  • PHP214 - SHOULD DRUG PRICES DIFFER BY INDICATION? OUTLINING THE DEBATE ON INDICATION-BASED PRICING AND HOW IT HAS BEEN IMPLEMENTED

    Oct 1, 2018, 00:00

  • PCN189 - ANALYSIS COST / UTILITY OF THE THERAPEUTIC THERAPY TREATMENT OF LUNG CANCER IN A UNIVERSITY HOSPITAL OF SPAIN

    Oct 1, 2018, 00:00

  • PCV108 - PRESCRIBING CHOICE AND THE COST OF ANTICOAGULATION IN ATRIAL FIBRILLATION- A REAL WORLD STUDY COMPARING HEALTHCARE EXPENDITURE WITH WARFARIN AND APIXABAN

    Oct 1, 2018, 00:00

  • PRS42 - COST-EFFECTIVENESS OF INDACATEROL/GLYCOPYRRONIUM IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN BRAZIL

    Oct 1, 2018, 00:00

  • PMS100 - COMPARISON OF LOW AND HIGH TOP BASKETBALL SHOES WITH RESERVE PLAYERS

    Oct 1, 2018, 00:00

  • PCN124 - DIRECT COST OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (AHSCT) FOR RELAPSED/REFRACTORY (RR) DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS FROM THE FRENCH HOSPITAL PERSPECTIVE

    Oct 1, 2018, 00:00

  • AC2 - USE OF MEDICINE PRICING AND REIMBURSEMENT POLICIES FOR UNIVERSAL HEALTH COVERAGE IN INDONESIA

    Oct 1, 2018, 00:00

  • PMD181 - PATIENT PREFERENCE FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT INHALERS- A DISCRETE CHOICE EXPERIMENT (DCE) IN FRANCE

    Oct 1, 2018, 00:00

  • PMD59 - DEVELOPING A COMPREHENSIVE TREATMENT COST COMPARISON MODEL IN SICKLE CELL DISEASE

    Oct 1, 2018, 00:00

  • PIN44 - ECONOMIC EVALUATION OF 60+ YEARS ADULT VACCINATION STRATEGY USING PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN SPAIN

    Oct 1, 2018, 00:00

  • PHP89 - CLASS CNN DRUGS IN ITALY- PURCHASE AND PRESCRIPTION BEHAVIOR IN ITALIAN HOSPITALS

    Oct 1, 2018, 00:00

  • PDB100 - STUDY ON AWARENESS REGARDING NEWER TRENDS IN DIABETES MEDICATION MANAGEMENT

    Oct 1, 2018, 00:00

  • PMS60 - CLINICAL AND ECONOMIC "REAL WORLD” ANALYSIS OF THE SWITCHING FROM REMICADE (INFLIXIMABE) BY REMSIMA (INFLIXIMAB BIOSSIMILAR) OF PLANSERV PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS.

    Oct 1, 2018, 00:00

  • ND3 - META-ANALYSIS OF REAL-WORLD ADHERENCE AND PERSISTENCE OF MAINTENANCE ONCE- OR TWICE-DAILY ORAL DISEASE-MODIFYING DRUGS (DIMETHYL FUMARATE, FINGOLIMOD, AND TERIFLUNOMIDE) IN MULTIPLE SCLEROSIS

    Oct 1, 2018, 00:00

  • PMU119 - PATIENT PREFERENCES IN THE TREATMENT OF PERIODONTAL DISEASE- A LATENT CLASS ANALYSIS

    Oct 1, 2018, 00:00

  • PMH32 - ECONOMIC IMPACT OF OPIOID DEPENDENCE IN GERMANY- A COST OF ILLNESS STUDY FOCUSSING ON PATIENTS IN OPIOID MAINTENANCE TREATMENT

    Oct 1, 2018, 00:00

  • PHP329 - THE REGISTRY EVALUATION AND QUALITY STANDARDS TOOL (REQUEST) FOR HEALTH TECHNOLOGY ASSESSMENT FROM AN OUTCOMES ASSESSMENT PERSPECTIVE

    Oct 1, 2018, 00:00

  • PSS33 - SECUKINUMAB AS FIRST BIOLOGIC TREATMENT- A COST PER RESPONDER ANALYSIS COMPARED WITH LICENSED BIOLOGICS, FOR MODERATE TO SEVERE PSORIASIS IN ARGENTINA

    Oct 1, 2018, 00:00

  • PMD58 - A PROSPECTIVE, RANDOMIZED TIME-AND-MOTION STUDY COMPARING RATE OF PROCESSING TECHNIQUES IN AUTOLOGOUS FAT GRAFTING- AN ECONOMIC ANALYSIS

    Oct 1, 2018, 00:00

  • PSY182 - A TARGETED REVIEW OF HAEMATOLOGY SINGLE TECHNOLOGY APPRAISALS (STAS) BY NICE SINCE THE INTRODUCTION OF THE NEW CANCER DRUGS FUND (CDF)

    Oct 1, 2018, 00:00

  • PUK16 - COST-EFFECTIVENESS OF TOLVAPTAN IN CANADIAN PATIENTS WITH AUTOSOMAL POLYCYSTIC KIDNEY DISEASE- AN ADAPTATION OF THE ADPKD OUTCOMES MODEL

    Oct 1, 2018, 00:00

  • PMD14 - PDL1 TESTING PATTERNS IN PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER IN ISRAEL - AN ANALYSIS OF REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PRS99 - IMPACT OF COUGH AND MUCUS ON THE EMOTIONAL AND PSYCHOSOCIAL WELLBEING IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE- A QUALITATIVE PATIENT ONLINE BULLETIN BOARD STUDY

    Oct 1, 2018, 00:00

  • PIN111 - IMPACT OF VARIATION IN INFLUENZA VACCINATION SCHEDULES AND DECISION-MAKING CRITERIA ON PATIENT OUTCOMES IN EUROPEAN COUNTRIES

    Oct 1, 2018, 00:00

  • PRM264 - DOES THE DESIGN OF A DISCRETE CHOICE ANALYSIS INFLUENCE ITS RESULTS? AN EXAMPLE STUDY OF WOMEN'S PREFERENCES FOR CONTRACEPTIVE PRODUCTS

    Oct 1, 2018, 00:00

  • PRM157 - THE IMPACT OF LANDMARK RESPONSE ON OVERALL SURVIVAL- IMPLICATIONS FOR THE ECONOMIC EVALUATION OF IMMUNE-THERAPY (I-O) TREATMENT IN SMALL CELL LUNG CANCER (SCLC)

    Oct 1, 2018, 00:00

  • PCN336 - TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCN212 - PREVALENCE OF CANCER AMONG WOMEN IN A TERTIARY TEACHING HOSPITAL IN LAGOS SOUTHWEST NIGERIA- A PHARMACOEPIDEMIOLOGICAL AND EVIDENCE BASED SURVEY

    Oct 1, 2018, 00:00

  • PSS21 - HEALTH INSURANCE TREATMENT COST OF LICHEN PLANUS IN HUNGARY- COST OF ILLNESS STUDY BASED ON REAL WORLD DATA

    Oct 1, 2018, 00:00

  • PCN72 - BUDGET IMPACT ANALYSIS OF TISAGENLECLEUCEL FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN ENGLAND

    Oct 1, 2018, 00:00

  • PCV142 - ADHERENCE TO ORAL ANTICOAGULATION TREATMENT IN ATRIAL FIBRILLATION AND THE IMPACT OF PATIENT SATISFACTION

    Oct 1, 2018, 00:00

  • PSY207 - IS LATE NIGHT EATING LINKED TO CHILDHOOD OBESITY? A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PHP187 - BEST PRACTICES FOR REAL WORLD EVIDENCE (RWE) COLLECTION FOR CELL AND GENE THERAPIES

    Oct 1, 2018, 00:00

  • PSS43 - DUPILUMAB IMPROVES ABSENTEEISM IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS COMPARED WITH PLACEBO IN PHASE 3 LIBERTY AD SOLO STUDIES

    Oct 1, 2018, 00:00

  • PRM58 - IMPACT OF FUTURE COSTS IN COST-EFFECTIVENESS ANALYSES AND A COMPARISON OF DIRECT AND INDIRECT METHODS USING MODELS OF CABAZITAXEL IN PROSTATE CANCER AND CLOPIDOGREL IN ACUTE CORONARY SYNDROME

    Oct 1, 2018, 00:00

  • PHP118 - IMPACT OF COHORT TEMPORARY AUTHORISATION FOR USE ON PRICE IN FRANCE

    Oct 1, 2018, 00:00

  • PHP158 - DEMAND FOR SECOND OPINIONS IN THE PAEDIATRIC POPULATION- A SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PHP243 - DO DISEASE SEVERITY AND/OR QUALITY OF CLINICAL DATA INFLUENCE PRICING POLICY IN FRANCE? AN ANALYSIS ON ORPHAN DRUGS AND BLOOD CANCERS TREATMENTS

    Oct 1, 2018, 00:00

  • PHP286 - RESPONSES OF ISPOR MEMBERS TO THE RECOMMENDATIONS OF THE SPECIAL TASK FORCE ON US VALUE ASSESSMENT FRAMEWORKS

    Oct 1, 2018, 00:00

  • PIN2 - IMPACT OF ADHERENCE TO HEDIS MEASURES ON THE QUALITY OF CARE FOR PEDIATRIC PATIENTS WITH PHARYNGITIS- EVIDENCE FROM A LARGE HEALTH PLAN

    Oct 1, 2018, 00:00

  • PCV153 - ELICITING PUBLIC PREFERENCES FOR REORGANIZATION OF VASCULAR SERVICES IN THE UK

    Oct 1, 2018, 00:00

  • PCN1 - REAL-WORLD EFFECTIVENESS AND TOLERABILITY OF SMALL-CELL LUNG CANCER (SCLC) TREATMENTS- A SYSTEMATIC LITERATURE REVIEW (SLR)

    Oct 1, 2018, 00:00

  • PCP67 - REGULATORY REQUIREMENTS AND SCIENTIFIC RATIONALE FOR BIOSIMILAR- US VS. EUROPEAN UNION.

    Oct 1, 2018, 00:00

  • PRM49 - MEASUREMENT AND VALUATION OF PRODUCTIVITY IN HEALTH ECONOMIC EVALUATIONS

    Oct 1, 2018, 00:00

  • PRM15 - PRE-APPROVAL SIMULATION OF REAL-WORLD OUTCOMES- DEVELOPMENT OF A METHODOLOGICAL FRAMEWORK

    Oct 1, 2018, 00:00

  • PP4 - ONE SIZE DOES NOT FIT ALL- HETEROGENEOUS PATIENT PREFERENCES AND TRADEOFFS FOR ANTIRETROVIRAL THERAPY - RESULTS OF A DISCRETE CHOICE EXPERIMENT

    Oct 1, 2018, 00:00

  • PCP6 - HOW TO INTRODUCE MULTI-INDICATION BASED PRICING IN FINLAND?

    Oct 1, 2018, 00:00

  • PIH39 - THE ASSOCIATION BETWEEN THE DIFFICULTIES IN THE ENTRANCE EXAM FOR MEDICAL UNIVERSITY AND PHYSICIANS' CAREER CHOICE- EVIDENCE FROM JAPAN

    Oct 1, 2018, 00:00

  • PHP102 - ARE SPECIFIC METHODOLOGICAL FRAMEWORKS REQUIRED FOR THE ECONOMIC EVALUATION OF GENE THERAPIES?

    Oct 1, 2018, 00:00

  • PCP47 - TAMING THE TORNADO CHART- SIMPLIFYING ONE-WAY SENSITIVITY ANALYSES FOR LARGE-SCALE MULTI-PARAMETER MODELS

    Oct 1, 2018, 00:00

  • Researchers, Patients, and Stakeholders Evaluating Comparative-Effectiveness Research- A Mixed-Methods Study of the PCORI Reviewer Experience

    Oct 1, 2018, 00:00

  • PDB88 - ADVENT OF MOBILE PLATFORMS LEVERAGES MULTISTAKEHOLDER COLLABORATION TO DRIVE OUTCOMES IN DIABETES

    Oct 1, 2018, 00:00

  • PMD65 - ECONOMIC VALUE OF NARROW BAND IMAGING VERSUS WHITE LIGHT ENDOSCOPY FOR THE MANAGEMENT OF NON-MUSCLE INVASIVE BLADDER CANCER- COST-CONSEQUENCE MODEL

    Oct 1, 2018, 00:00

  • PSY107 - COST-EFFECTIVENESS OF BUDESONIDE IN MICROSCOPIC COLITIS PATIENTS IN THE CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PCN301 - HEALTH TECHNOLOGY ASSESSMENT FOR CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPIES FOR CANCER

    Oct 1, 2018, 00:00

  • PRS21 - ECONOMIC IMPACT OF DELAYING INITIATION WITH MULTIPLE INHALER MAINTENANCE TRIPLE THERAPY TREATMENT IN SPANISH COPD PATIENTS

    Oct 1, 2018, 00:00

  • French Patients with Hepatitis C Treated with Direct-Acting Antiviral Combinations- The Effect on Patient-Reported Outcomes

    Oct 1, 2018, 00:00

  • PHP249 - ARE TRADITIONAL MANAGED ENTRY AGREEMENTS SUITABLE FOR POTENTIALLY, CURATIVE GENE/CELL THERAPIES?

    Oct 1, 2018, 00:00

  • PMS89 - DEVELOPMENT OF AN OUTCOMES MEASUREMENT TOOL TO EVALUATE THE QUALITY OF BIOLOGIC SWITCH IN PSORIATIC ARTHRITIS

    Oct 1, 2018, 00:00

  • PRM91 - DATA-DRIVEN AND INSIGHTFUL- AN ANALOGUE ANALYSIS TOOL FOR RAPID AND TARGETED PRICING EXPLORATION

    Oct 1, 2018, 00:00

  • PCN213 - FINANCING EXPENSIVE ANTICANCER DRUGS IN HOSPITALS- TOWARDS TRANSPARENCY TO IMPROVE PATIENT ACCESS

    Oct 1, 2018, 00:00

  • MD4 - DIGITAL HEALTHCARE EVALUATION AT NICE- AN EVOLVING PROCESS

    Oct 1, 2018, 00:00

  • CN8 - COST-EFFECTIVENESS ANALYSIS OF ORAL CANCER SCREENING IN TAIWAN- A REAL WORLD DATA ANALYSIS

    Oct 1, 2018, 00:00

  • PMD136 - THE FEASIBILITY OF APPLYING THE MULTIPLE CRITERIA DECISION ANALYSIS FOR THE EVALUATION OF MEDICAL DEVICES IN THE CONTEXT OF HOSPITAL-BASED HEALTH TECHNOLOGY ASSESSMENT IN TURKEY

    Oct 1, 2018, 00:00

  • PMS88 - REAL WORLD PERSISTENCE AND ADHERENCE WITH ORAL BISPHOSPHONATES FOR OSTEOPOROSIS - A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PSY195 - HUMANISTIC BURDEN ASSOCIATED WITH RPE65 GENE MUTATION RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PHP148 - SELF-PERCEIVED HEALTH INEQUALITIES BY INCOME DISTRIBUTION IN EUROPEAN UNION

    Oct 1, 2018, 00:00

  • PCN271 - A REAL-WORLD DATA STUDY REGARDING HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH BREAST CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PRM106 - ADVANCED NMA TECHNIQUES IN NICE HTA SUBMISSIONS

    Oct 1, 2018, 00:00

  • PSY154 - ECONOMIC BURDEN OF BETA-THALASSEMIA- LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN352 - UTILITY VALUES FOR ADVANCED HEPATOCELLULAR CARCINOMA PATIENTS IN FRANCE RECEIVING SELECTIVE INTERNAL RADIATION THERAPY (SIRT) WITH Y-90 RESIN MICROSPHERES VERSUS SORAFENIB USING EQ-5D SCORES MAPPED FROM EORTC-QLQ-C30 RESULTS

    Oct 1, 2018, 00:00

  • PMS121 - EVALUATION OF THE WORK PRODUCTIVITY IN ANKYLOSING SPONDYLITIS (AS) AND PSORIATIC ARTHRITIS (PSA) PATIENTS BEFORE AND AFTER THE START OF ADALIMUMAB THERAPY IN DAILY PRACTICE IN BELGIUM (SPACTIVE STUDY)

    Oct 1, 2018, 00:00

  • PCN26 - ASSESSING THE POTENTIAL VALUE OF AN INNOVATIVE ONCOLOGY THERAPY FROM THE HEALTH TECHNOLOGY ASSESSMENT (HTA) PERSPECTIVE- MARRYING CLINICAL VALUE FRAMEWORKS WITH ECONOMIC ASSESSMENT METHODOLOGY

    Oct 1, 2018, 00:00

  • PCV48 - TOTAL ANNUAL HEALTHCARE COSTS OF HEART FAILURE BETWEEN 2005 AND 2014- A RETROSPECTIVE, POPULATION-BASED STUDY IN SWEDEN

    Oct 1, 2018, 00:00

  • PDB12 - CARDIOVASCULAR SAFETY OF EMPAGLIFLOZIN VERSUS GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS- SYSTEMATIC LITERATURE REVIEW AND INDIRECT COMPARISONS

    Oct 1, 2018, 00:00

  • PCV101 - HYPERTRIGLYCERIDEMIA AND RISK OF ALL-CAUSE MORTALITY AND MAJOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) EVENTS IN CLINICAL PRACTICE- THE TG-REAL STUDY

    Oct 1, 2018, 00:00

  • PCN176 - A COST-EFFECTIVENESS ANALYSIS OF ATEZOLIZUMAB VERSUS DOCETAXEL FOR PREVIOUSLY TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER IN BELGIUM

    Oct 1, 2018, 00:00

  • PCV133 - ADHERENCE SUPPORT IN COMMUNITY PHARMACIES - THE PERCEPTION OF GERMAN PHARMACISTS

    Oct 1, 2018, 00:00

  • PMU123 - THE RELATIONSHIP BETWEEN INDIVIDUAL-LEVEL DEPRIVATION WITH HEALTH-RELATED QUALITY OF LIFE IN THE GENERAL POPULATION

    Oct 1, 2018, 00:00

  • PMD18 - IMPACT OF DIFFERENT IOL MATERIALS ON THE INCIDENCE OF ND-YAG LASER CAPSULOTOMY- A NETWORK META-ANALYSIS

    Oct 1, 2018, 00:00

  • PHP161 - ASSESSING THE NET PRICE LEVEL OF GENERICS IN GREECE- THE EFFECT OF COMPULSORY PAYBACKS

    Oct 1, 2018, 00:00

  • PND69 - COST-UTILITY ANALYSIS OF COMMUNITY OCCUPATIONAL THERAPY IN DEMENTIA (COTID-UK) VERSUS USUAL CARE- RESULTS FROM VALID, A MULTI-SITE RANDOMIZED CONTROLLED TRIAL IN THE UK

    Oct 1, 2018, 00:00

  • PHP203 - RELATIVE VALUE OF EVIDEM MCDA FRAMEWORK FOR REFLECTIVE DRUG EVALUATION AMONG HOSPITAL PHARMACISTS IN PORTUGAL

    Oct 1, 2018, 00:00

  • PCN40 - A RETROSPECTIVE STUDY ON PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PRESCRIBED ABIRATERONE ACETATE + PREDNISONE PRIOR TO CHEMOTHERAPY IN SWEDEN, NORWAY AND DENMARK

    Oct 1, 2018, 00:00

  • Assessing Rationality in Discrete Choice Experiments in Health- An Investigation into the Use of Dominance Tests

    Oct 1, 2018, 00:00

  • PDB122 - THE EFFECTS OF TYPE 2 DIABETES ON HEALTH-RELATED QUALITY OF LIFE IN THE FINNISH POPULATION AS MEASURED WITH EQ-5D-5L

    Oct 1, 2018, 00:00

  • PRM118 - ADJUSTMENT FOR SUBSEQUENT THERAPIES RECEIVED- THE IMPACT ON OUTCOMES OF AN ECONOMIC MODEL OF NIVOLUMAB+IPILIMUMAB IN FIRST LINE RENAL CELL CARCINOMA

    Oct 1, 2018, 00:00

  • PMD176 - MEDICATION ADHERENCE ASCERTAINED BY A DIGITAL OBSERVATIONAL STUDY APPROACH USING A MEDICAL APP- A PILOT STUDY AMONG PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH INTERFERON BETA-1B

    Oct 1, 2018, 00:00

  • PRM35 - INCREMENTAL COST EFFECTIVENESS RATIO (ICER) THRESHOLD, THE END OF HORIZONTAL EQUITY?

    Oct 1, 2018, 00:00

  • PHP289 - AN EXAMINATION OF DELAYS DURING NICE TECHNOLOGY APPRAISAL REVIEWS

    Oct 1, 2018, 00:00

  • PRM169 - RESPONSIVENESS OF THE EQ-5D-5L AND EQ-5D-3L IN PATIENTS FOLLOWING TOTAL HIP OR KNEE REPLACEMENT

    Oct 1, 2018, 00:00

  • PMD93 - THE COMPARATIVE PHARMACOECONOMIC ANALYSIS OF USING DIFFERENT TYPES OF MONOFOCAL INTRAOCULAR LENSES FOR CATARACT SURGERY IN RUSSIA

    Oct 1, 2018, 00:00

  • ND1 - AMBULATORY FUNCTION IN DUCHENNE MUSCULAR DYSTROPHY (DMD)- THE CHARACTERISTIC TRAJECTORY AND VARIATION ACROSS INDIVIDUALS

    Oct 1, 2018, 00:00

  • PSS68 - THE MOST INFLUENTIAL DRIVERS OF PSORIASIS PATIENTS’ TREATMENT CHOICE- A DISCRETE CHOICE EXPERIMENT SURVEY IN THE US

    Oct 1, 2018, 00:00

  • PRS46 - INFORMING THE PATHWAY OF COPD TREATMENT (IMPACT STUDY) - SINGLE INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS FF/VI IN PATIENTS WITH COPD- COST-EFFECTIVENESS ANALYSIS FROM A SOCIETAL PERSPECTIVE IN QUEBEC

    Oct 1, 2018, 00:00

  • PMU113 - TIME-DEPENDENT VARIATION OF PRO SCORES IN CHRONIC CONDITIONS- A SCOPING REVIEW

    Oct 1, 2018, 00:00

  • PND15 - TREATMENT AND CHARACTERISTICS OF PEDIATRIC PATIENTS WITH FOCAL EPILEPSY IN GERMANY

    Oct 1, 2018, 00:00

  • PRM111 - APPLICATION AND ACCEPTANCE OF COMPLEX SURVIVAL EXTRAPOLATION METHODS IN HTA SUBMISSIONS

    Oct 1, 2018, 00:00

  • PCN325 - COMPARING THE ROLE OF DIFFERENT SPECIALITIES IN THE MANAGEMENT OF PROSTATE CANCER IN FRANCE AND ITALY- INSIGHTS FROM A REAL-WORLD STUDY

    Oct 1, 2018, 00:00

  • PSY161 - A RAPID LITERATURE REVIEW OF REAL-WORLD EVIDENCE IN MULTIPLE MYELOMA- PATIENT CHARACTERISTICS AND HEALTH OUTCOMES

    Oct 1, 2018, 00:00

  • PSY223 - QUALITATIVE RESEARCH IN HAEMOPHILIA A- EMICIZUMAB TRANSFORMS LIFESTYLE OF PATIENTS WITH INHIBITOR

    Oct 1, 2018, 00:00

  • PSY5 - PATIENTS WITH RELAPSING ANCA-ASSOCIATED VASCULITIS (AAV) EXPERIENCE UNMET NEEDS AND UTILISE SIGNIFICANT HEALTHCARE RESOURCES

    Oct 1, 2018, 00:00

  • PCN191 - COST-EFFECTIVENESS OF MONITORING ENDOXIFEN LEVELS IN BREAST CANCER PATIENTS ADJUVANTLY TREATED WITH TAMOXIFEN

    Oct 1, 2018, 00:00

  • PIN74 - A SYSTEMATIC REVIEW ON ECONOMIC EVALUATION OF ROTAVIRUS VACCINATION

    Oct 1, 2018, 00:00

  • PMU114 - COMPARING A DIRECT AND STAGED APPROACH TO ITEM SELECTION IN A MULTI-DIMENSIONAL PATIENT-REPORTED OUTCOME MEASURE

    Oct 1, 2018, 00:00

  • PGI24 - COST-UTILITY ANALYSIS OF VITAMINE E AND PIOGLITAZONE IN ADDITION TO 2 YEARS OF LIFE-STYLE MODIFICATION THERAPY FOR NON-ALCOHOLIC STEATOHEPATITIS PATIENTS IN JAPAN

    Oct 1, 2018, 00:00

  • PMD38 - CELL-FREE FETAL DNA AS A CONTINGENT PRENATAL SCREENING OF TRISOMIES CONDITIONAL TO A RISK ≥ 1-1,000 FOR ITALIAN PREGNANT WOMEN- AN ECONOMIC EVALUATION

    Oct 1, 2018, 00:00

  • PDB51 - RESULTS OF THE COSMODIA STUDY- ESTIMATING THE IMPACT ON THE NUMBER OF CLINICAL COMPLICATIONS AND THE ASSOCIATED POTENTIAL FINANCIAL BENEFIT AS A CONSEQUENCE OF BETTER MANAGEMENT OF GLYCAEMIC CONTROL IN PEOPLE WITH TYPE 2 DIABETES IN ...

    Oct 1, 2018, 00:00

  • PSY19 - USING A BAYESIAN NETWORK META-ANALYSIS (NMA) TO COMPARE FERRIC MALTOL TO TREATMENTS FOR IRON DEFICIENCY AND IRON DEFICIENCY ANAEMIA EXCLUDING CHF AND CKD PATIENTS

    Oct 1, 2018, 00:00

  • PCN270 - HOSPITAL RESOURCES USE AND COSTS ASSOCIATED WITH 6 PREVALENT CANCER IN SPAIN, A REALWORLD DATA STUDY

    Oct 1, 2018, 00:00

  • PMU42 - ECONOMIC AND ORGANIZATIONAL IMPACT OF A VASCULAR ACCESS TEAM IN AN ITALIAN HOSPITAL

    Oct 1, 2018, 00:00

  • PCN322 - AN EXAMPLE OF RWE USED FOR HTA EVALUATION- ERLOTINIB RENEGOTIATION IN ITALY

    Oct 1, 2018, 00:00

  • PRM155 - JOINT MODELING OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL

    Oct 1, 2018, 00:00

  • PMH14 - SOCIAL FUNCTIONING AT ADMISSION IN PATIENTS WITH MENTAL ILLNESS HOSPITALIZED COMPULSORILY BY PREFECTURAL GOVERNORS IN ACCORDANCE WITH THE PROVISIONS OF ARTICLE 29 OF THE JAPANESE MENTAL HEALTH ACT.

    Oct 1, 2018, 00:00

  • PSY85 - ECONOMIC BURDEN ASSOCIATED WITH RPE65 GENE RELATED INHERITED RETINAL DYSTROPHIES- A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PDB42 - PRICE ANALYSIS OF ANTIDIABETIC DRUGS MARKETED IN ARABIC COUNTRIES

    Oct 1, 2018, 00:00

  • PMS81 - CONSENSUS ON THE MEASUREMENT INSTRUMENTS TO EVALUATE THE EFFECTIVENESS OF BIOLOGICAL TREATMENT IN PSORIATIC ARTHRITIS- MERECES STUDY.

    Oct 1, 2018, 00:00

  • PRM102 - ANALYZING REAL-WORLD DATA TO TARGET HARD-TO-IDENTIFY PATIENT POPULATIONS FOR CLINICAL TRIALS- A CASE STUDY IN METASTATIC BREAST CANCER

    Oct 1, 2018, 00:00

  • PRS58 - PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)- WHAT HAPPENS BEFORE THE DIAGNOSIS? A REAL-WORLD, RETROSPECTIVE, PRIMARY CARE DATABASE ANALYSIS

    Oct 1, 2018, 00:00

  • PHP83 - THE IMPACT OF THE NEW INNOVATIVE ALGORITHM IN ITALY

    Oct 1, 2018, 00:00

  • PSY90 - RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE DATA TO ASSESS ADHERENCE, PHARMACOUTILIZATION AND COSTS OF BIOLOGICAL THERAPY TREATMENT OF PSORIASIS IN SOUTHERN ITALIAN SETTING

    Oct 1, 2018, 00:00

  • PRM271 - REDUCING LENGTH OF AN OUTCOMES-BASED CONTRACT THROUGH ACTIVE-LEARNING BY PAYERS

    Oct 1, 2018, 00:00

  • PHP257 - AN ANALYSIS AND FEASIBILITY ASSESSMENT OF INDICATION-SPECIFIC PRICING AS A MEANS TO IMPROVE PATIENT ACCESS TO MEDICINES AND REINFORCE INCENTIVES FOR INNOVATION

    Oct 1, 2018, 00:00

  • PCP48 - STABILITY OF RESULTS IN SIMULATION BASED HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PMU75 - IS ADOPTING A LOW PRICE STRATEGY TO GAIN MARKET ACCESS COMPATIBLE WITH A VIABLE GENE/CELL THERAPY BUSINESS?

    Oct 1, 2018, 00:00

  • PHP303 - WHAT ARE THE KEY CONSIDERATIONS FOR SEEKING PAYER SCIENTIFIC ADVICE IN THE EU?

    Oct 1, 2018, 00:00

  • PCV8 - IMPACT OF EXERCISE-BASED REHABILITATION IN PATIENTS WITH HEART FAILURE (EXTRAMATCH II) ON EXERCISE CAPACITY AND HEALTH-RELATED QUALITY OF LIFE- A META-ANALYSIS OF INDIVIDUAL PARTICIPANT DATA FROM RANDOMISED TRIALS

    Oct 1, 2018, 00:00

  • PRS18 - POTENTIAL SAVINGS ACHIEVED THROUGH SWITCHING COPD PATIENTS FROM ICS-CONTAINING REGIMENS TO LAMA+LABA- A SPANISH PERSPECTIVE.

    Oct 1, 2018, 00:00

  • PSS48 - PARENTS’ BELIEFS AND KNOWLEDGE ABOUT THE MANAGEMENT OF OTITIS MEDIA IN UNAIZAH, SAUDIARABIA- A QUALITATIVE STUDY

    Oct 1, 2018, 00:00

  • PMD25 - RISK FACTORS ASSOCIATED WITH PCO FOLLOWING CATARACT SURGERY- REAL-WORLD OUTCOMES STUDY IN THE UNITED KINGDOM (UK)

    Oct 1, 2018, 00:00

  • PND158 - CHANGES IN SLEEP PATTERNS AFTER VAGUS NERVE STIMULATION, DEEP BRAIN STIMULATION OR EPILEPSY SURGERY- SYSTEMATIC REVIEW OF THE LITERATURE

    Oct 1, 2018, 00:00

  • PHP131 - WHAT USE IS DISTRIBUTED LEDGER TECHNOLOGY IN REAL-WORLD PRACTICE? - A SYSTEMATIC LITERATURE REVIEW

    Oct 1, 2018, 00:00

  • PCN118 - THE BURDEN OF CANCER IN SPAIN

    Oct 1, 2018, 00:00

  • PRM125 - SYSTEMATIC REVIEW OF META-MODELING APPLICATIONS AND OPPORTUNITIES FOR ADVANCED ANALYSES WITH HEALTH ECONOMIC MODELS

    Oct 1, 2018, 00:00

  • PSY152 - IMPACT OF FATIGUE ON RESOURCE UTILIZATION AND HEALTHCARE COSTS IN AUTOIMMUNE (AI) DISEASE

    Oct 1, 2018, 00:00

  • PCN66 - LANDMARK ANALYSES IN ONCOLOGY – SEEING BEYOND THE SURFACE AND PROPOSING A STRUCTURED DATA ANALYSIS CHECKLIST

    Oct 1, 2018, 00:00

  • PIH46 - ANALYSING THE ATTITUDE OF OLD AGE HOME RESIDENTS ON POLYPHARMACY AND DEPRESCRIBING OF MEDICATIONS IN MANGALORE, KARNATAKA.

    Oct 1, 2018, 00:00

  • PHP268 - THE HUNGARIAN PALLIATIVE CARE POSITION, CHALLENGES, BREAK POINTS

    Oct 1, 2018, 00:00

  • PIN76 - IMPACT OF TRANSFERRING ARTS DISPENSING FROM HOSPITAL TO COMMUNITY PHARMACIES- A PILOT STUDY IN PORTUGAL

    Oct 1, 2018, 00:00

  • PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE

    Oct 1, 2018, 00:00

  • PGI33 - URSODEOXYCHOLIC ACID TO GALLSTONE DISSOLUTION THERAPY IN ASYMPTOMATIC CHOLELITHIASIS PATIENTS- A SYSTEMATIC REVIEW OF THE EFFICACY AND SAFETY

    Oct 1, 2018, 00:00

  • PRS8 - EFFECTS OF SMOKIMG CESSATION ON HEALTH OUTCOMES AMONG COPD PATIENTS IN SOUTH KOREA- 12 YEARS FOLLOW-UP

    Oct 1, 2018, 00:00

  • PRM9 - A LONGITUDINAL, ITEM-LEVEL ANALYSIS METHODOLOGY TO SUPPORT THE INTERPRETABILITY OF MULTI-ITEM PATIENT-REPORTED OUTCOMES

    Oct 1, 2018, 00:00

  • PSY174 - IS PHARMACOKINETIC DRIVEN THERAPY OF POTENTIAL BENEFIT IN HEMOPHILIA?

    Oct 1, 2018, 00:00

  • PCV67 - STAR ANALYSIS AND FORECAST MODELLING TO ESTIMATE VALUE FOR MONEY OF ORAL ANTICOAGULANTS

    Oct 1, 2018, 00:00

  • PCV155 - EVALUATING THE IMPACT OF PHARMACIST INTERVENTION ON DISEASE KNOWLEDGE, ILLNESS PERCEPTIONS, AND BELIEF TOWARDS MEDICATIONS IN ACUTE CORONARY SYNDROME PATIENTS IN HONG KONG

    Oct 1, 2018, 00:00

  • PHP47 - EVALUATING PATIENTS’, PHYSICIANS’ AND PHARMACISTS’ PERCEPTION REGARDING GENERIC MEDICINES IN GONDAR, NORTHWEST ETHIOPIA

    Oct 1, 2018, 00:00

  • PSY162 - EVALUATION OF DIRECT COSTS AND TREATMENT PATTERNS ASSOCIATED WITH THE MANAGEMENT OF NEUROPATHIC PAIN IN COLOMBIA

    Oct 1, 2018, 00:00

  • PIH31 - USE OF ADMINISTRATIVE DATA FOR ASSESSMENT OF MEDICATION PRESCRIPTION PRACTICE IN TWO ITALIAN SETTINGS

    Oct 1, 2018, 00:00

  • PDB17 - REAL-WORLD DOSING BEHAVIOURS AND OUTCOMES WHEN SWITCHING TO IDEGLIRA FROM A FREE COMBINATION OF INSULIN AND GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY

    Oct 1, 2018, 00:00

  • PCN142 - COST-EFFECTIVENESS ANALYSIS OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF ADULTS WITH RELAPSED OR REFRACTORY B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN BULGARIA

    Oct 1, 2018, 00:00

  • PCV99 - ANALYSIS OF MEAN AGE OF PATIENTS REGISTERED WITH ACUTE MYOCARDIAL INFARCTION IN HUNGARY, 2010-2017

    Oct 1, 2018, 00:00

  • PDB5 - EFFECT OF STATINS USAGE ON INCIDENCE OF PERIPHERAL NEUROPATHY AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Oct 1, 2018, 00:00

  • PCN356 - HOW SHOULD WE VALIDATE UTILITY MAPPING ALGORITHMS BEFORE USE? AN EXAMPLE IN NON-SMALL CELL LUNG CANCER

    Oct 1, 2018, 00:00

  • PCN163 - COST-EFFECTIVENESS OF ADD-ON PERTUZUMAB COMBINED WITH TRASTUZUMAB AND DOCETAXEL VERSUS PLACEBO AS TREATMENT OF HER-2 POSITIVE METASTATIC BREAST CANCER IN CZECH REPUBLIC

    Oct 1, 2018, 00:00

  • PRM65 - DIFFERENT COST EFFECTIVENESS MODELS USED FOR ECONOMIC EVALUATION IN MODERATE TO SEVERE PAINFUL DIABETIC NEUROPATHY OR POST-HERPETIC NEURALGIA

    Oct 1, 2018, 00:00

  • PMD159 - ASSESSMENT OF THE MARKET ACCESS POTENTIAL OF A NOVEL MEDICAL DEVICE AND APP COMBINATION FOR AN ORPHAN DISEASE

    Oct 1, 2018, 00:00

  • PMD137 - CARDIAC IMPLANT REGISTRIES 2006-2016- SYSTEMATIC REVIEW OF GLOBAL PRACTICES

    Oct 1, 2018, 00:00

  • PIN87 - PHYSICIAN PREFERENCES FOR THE TREATMENT OF CHRONIC HEPATITIS C VIRUS INFECTION- AN ADAPTIVE CONJOINT ANALYSIS

    Oct 1, 2018, 00:00

  • PHP154 - PRIVATE HEALTH SPENDING AND ACCESS TO HEALTHCARE OF UNEMPLOYED PEOPLE IN GREECE

    Oct 1, 2018, 00:00

  • PIH6 - DEVELOPMENT AND VALIDATION OF A SCREENING QUESTIONNAIRE TO DETECT HEAVY MENSTRUAL BLEEDING IN GYNAECOLOGY- THE SAMANTA QUESTIONNAIRE

    Oct 1, 2018, 00:00

  • PMS38 - COST EFFECTIVENESS ANALYSIS OF SECUKINUMAB VERSUS USTEKINUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS IN THE UNITED STATES

    Oct 1, 2018, 00:00

  • PCN247 - TREATMENT PATTERNS IN RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK (R/M SCCHN) POST PLATINUM-BASED THERAPY (PPBT) IN THE IMMUNO-ONCOLOGY (IO) ERA

    Oct 1, 2018, 00:00

  • PHP266 - MANAGED ACCESS PROGRAMS- A FIRST STEP FOR UK HTA?

    Oct 1, 2018, 00:00

  • PHP296 - MANAGED ACCESS AGREEMENTS (MAAS) AND CONTINUING DATA COLLECTION AFTER PROVISIONAL POSITIVE RECOMMENDATION FROM THE NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE (NICE)

    Oct 1, 2018, 00:00

  • PCN304 - APPROPRIATE COMPARATOR IN GERMAN AMNOG BENEFIT ASSESSMENTS IN MELANOMA – A DYNAMIC SITUATION

    Oct 1, 2018, 00:00

  • PCV21 - IMPACT OF GENETIC AND NON-GENETIC FACTORS ON CLOPIDOGREL EFFICACY

    Oct 1, 2018, 00:00

  • PRM234 - HAZARD RATIO ESTIMATION USING DIFFERENT METHODS- AN IMPACT ASSESSMENT

    Oct 1, 2018, 00:00

  • PHP350 - PERFORMANCE AND OUTCOMES BASED CONTRACTS IN THE EU AND USA- COMPARISON OF TRENDS AND RECENT DEVELOPMENTS

    Oct 1, 2018, 00:00

  • PCN205 - OUTCOMES OF DECISION AIDS USED IN ONCOLOGY- A SYSTEMATIC REVIEW

    Oct 1, 2018, 00:00

  • PMU38 - REVIEW OF STUDIES REPORTING ACTUAL PRICES FOR MEDICINES

    Oct 1, 2018, 00:00

  • PMS33 - CATEGORISING PATIENTS WITH RHEUMATOID ARTHRITIS USING TRAJECTORIES OF DISEASE ACTIVITY SCORE IN HUNGARY

    Oct 1, 2018, 00:00

  • PCP15 - WHY EUROPEAN CROSS-BORDER INITIATIVES ON DRUG PROCUREMENT MAY FAIL?

    Oct 1, 2018, 00:00

  • PHP220 - OLD DRUGS TURNED NEW FOR ULTRA ORPHAN DISEASE- A CHALLENGE FOR PAYERS OR FOR THE INDUSTRY?

    Oct 1, 2018, 00:00

  • PHP331 - IS IT ENOUGH TO HAVE IT IN THE VACCINATION PROGRAMME? AN EMPIRICAL ANALYSIS OF THE FACTORS THAT AFFECT INFLUENZA VACCINATION UPTAKE IN ADULTS IN GREECE

    Oct 1, 2018, 00:00
  • «
  • 51
  • 52
  • 53
  • 54 (current)
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • »